Short-circuiting long-lived humoral immunity by the heightened engagement of CD40 - PubMed (original) (raw)
Short-circuiting long-lived humoral immunity by the heightened engagement of CD40
Loren D Erickson et al. J Clin Invest. 2002 Mar.
Abstract
Agonistic alpha CD40 Ab's have been shown to be potent immune adjuvants for both cell- and humoral-mediated immunity. While enhancing short-lived humoral immunity, the administration of a CD40 agonist during thymus-dependent immune responses ablates germinal center formation, prematurely terminates the humoral immune response, blocks the generation of B cell memory, and prevents the generation of long-lived bone marrow plasma cells. Interestingly, some of these effects of heightened CD40 engagement could be mimicked by enhancing the magnitude of antigen-specific T cell help. Taken together, these studies demonstrate that as the magnitude of CD40 signaling intensifies, the fate of antigen-reactive B cells can be dramatically altered. These are the first studies to describe the multifaceted function of CD40 in determining the fate of antigen-reactive B cells and provide novel insights into how CD40 agonists can short-circuit humoral immunity.
Figures
Figure 1
αCD40 treatment aborts a GC phenotype and promotes extrafollicular localization of Tg B cells. (a) Total numbers of splenic Tg B cells (anti-NP idiotype+, B220+) were measured on day 7 after immunization. (b) Spleen or LN cells from naive (black line), immune/RIgG (red line), and immune/αCD40 (blue line) were stained with GC markers. Histograms shown represent the relative intensity of the indicated marker on Tg B cells (B220+ Id+). (c) Spleen cells from naive and immune IghCD40 transgenic mice treated with rat IgG or agonistic αhCD40 mAb were stained with GC markers. The percentage of total PNA+ GL7+ GC B cells are indicated in each panel. (d) Frozen sections from intact spleens were costained with B220 (green), CD4, and CD8 (red), and anti–NP idiotype (Id) 17.2.25 (blue) Ab’s, and analyzed by confocal microscopy. Objective: ×20; zoom 1.5. Data are representative of three independent experiments.
Figure 2
Administration of αCD40 reduces the duration of humoral immune responses. Serum αNP IgG1a levels were measured by ELISA on days indicated after immunization. Values are a composite of three mice per group. Data are representative of three experiments.
Figure 3
αCD40 administration prevents the generation of bone marrow ASCs. Cells from spleen and bone marrow were isolated from the indicated recipients on day 7 (a) and day 21 (b) after immunization and assayed for total NP-specific IgG1a or high-affinity NP-specific IgG1a (c) by ELISPOT using normalized numbers of Tg B cells. Results shown are representative of three independent experiments.
Figure 4
Administration of αCD40 upregulates Blimp-1 gene expression in Tg B cells. PCR amplification of the indicated transcript was performed using normalized amounts of cDNA isolated from purified splenic Tg B cells of recipients challenged with NP-Ficoll (TI immune), NP-KLH (TD immune), or NP-KLH and treated with αCD40 (TD immune + αCD40). Data are representative of three mice per group from two independent experiments.
Figure 5
Carrier-primed T cells prevent the acquisition of a GC phenotype in the spleen but not in the LN and differentially control the generation of long-lived Tg ASCs. (a) Total numbers of LN and splenic Tg B cells were quantified 5 days after challenge. (b) Tg cells from naive (shaded area) and immune (open area) recipients were stained for the expression of the indicated GC marker. Histograms shown represent the relative intensity on gated Tg cells isolated from LN and spleen. Data are representative of six experiments. (c) Frozen sections from intact spleen and LN were costained with B220 (green), CD4 and CD8 (red), and anti–NP Id 17.2.25 (blue) Ab’s, followed by confocal image analysis. Objective: ×20; zoom: 1.75. (d) Equivalent numbers of naive and immune Tg B cells isolated from spleen and LN of carrier-primed recipients were transferred into secondary recipients that received neither priming nor antigen. Total numbers of bone marrow NP-specific IgG1a ASCs were quantified by ELISPOT analysis 7 days after transfer. Data shown are representative of three independent experiments.
Similar articles
- Determinations of B cell fate in immunity and autoimmunity.
Noelle RJ, Erickson LD. Noelle RJ, et al. Curr Dir Autoimmun. 2005;8:1-24. doi: 10.1159/000082084. Curr Dir Autoimmun. 2005. PMID: 15564715 Review. - CD40 signaling drives B lymphocytes into an intermediate memory-like state, poised between naïve and plasma cells.
Upadhyay M, Priya GK, Ramesh P, Madhavi MB, Rath S, Bal V, George A, Vaidya T. Upadhyay M, et al. J Cell Physiol. 2014 Oct;229(10):1387-96. doi: 10.1002/jcp.24572. J Cell Physiol. 2014. PMID: 24482285 - Observations on memory B-cell development.
Gray D, Bergthorsdottir S, van Essen D, Wykes M, Poudrier J, Siepmann K. Gray D, et al. Semin Immunol. 1997 Aug;9(4):249-54. doi: 10.1006/smim.1997.0077. Semin Immunol. 1997. PMID: 9237931 Review. - Swiprosin-1/EFhd2 limits germinal center responses and humoral type 2 immunity.
Brachs S, Turqueti-Neves A, Stein M, Reimer D, Brachvogel B, Bösl M, Winkler T, Voehringer D, Jäck HM, Mielenz D. Brachs S, et al. Eur J Immunol. 2014 Nov;44(11):3206-19. doi: 10.1002/eji.201444479. Epub 2014 Sep 16. Eur J Immunol. 2014. PMID: 25092375 - The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells.
Ahonen C, Manning E, Erickson LD, O'Connor B, Lind EF, Pullen SS, Kehry MR, Noelle RJ. Ahonen C, et al. Nat Immunol. 2002 May;3(5):451-6. doi: 10.1038/ni792. Epub 2002 Apr 22. Nat Immunol. 2002. PMID: 11967542 Free PMC article.
Cited by
- B cells secrete functional antigen-specific IgG antibodies on extracellular vesicles.
Rival C, Mandal M, Cramton K, Qiao H, Arish M, Sun J, McCann JV, Dudley AC, Solga MD, Erdbrügger U, Erickson LD. Rival C, et al. Sci Rep. 2024 Jul 23;14(1):16970. doi: 10.1038/s41598-024-67912-y. Sci Rep. 2024. PMID: 39043800 Free PMC article. - B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages.
Nobari ST, Nojadeh JN, Talebi M. Nobari ST, et al. J Transl Med. 2022 Feb 10;20(1):82. doi: 10.1186/s12967-022-03285-y. J Transl Med. 2022. PMID: 35144648 Free PMC article. Review. - A Posttranscriptional Pathway of CD40 Ligand mRNA Stability Is Required for the Development of an Optimal Humoral Immune Response.
Narayanan B, Prado de Maio D, La Porta J, Voskoboynik Y, Ganapathi U, Xie P, Covey LR. Narayanan B, et al. J Immunol. 2021 Jun 1;206(11):2552-2565. doi: 10.4049/jimmunol.2001074. Epub 2021 May 24. J Immunol. 2021. PMID: 34031147 Free PMC article. - Experimental modeling of desensitization: What have we learned about preventing AMR?
Kwun J, Knechtle S. Kwun J, et al. Am J Transplant. 2020 Jun;20 Suppl 4(Suppl 4):2-11. doi: 10.1111/ajt.15873. Am J Transplant. 2020. PMID: 32538533 Free PMC article. Review. - Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques.
Silva de Castro I, Gordon SN, Liu J, Bissa M, McKinnon K, Trinh HV, Doster MN, Schifanella L, Liyanage NP, Cao J, Cheng O, Foulds K, Roederer M, Koup RA, Shen X, Tomaras GD, Venzon DJ, Forthal DN, Fouts T, Montefiori DC, Tartaglia J, Rao M, Ostrowski M, Franchini G, Vaccari M. Silva de Castro I, et al. J Virol. 2020 Feb 28;94(6):e01933-19. doi: 10.1128/JVI.01933-19. Print 2020 Feb 28. J Virol. 2020. PMID: 31896599 Free PMC article.
References
- Foy T, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand gp39. Annu Rev Immunol. 1996;14:591–617. - PubMed
- Dullforce P, Sutton DC, Heath AW. Enhancement of T cell-independent immune responses in vivo by CD40 antibodies. Nat Med. 1998;4:88–91. - PubMed
- Schoenberger SP, Toes REM, van der Voort EIH, Offringa R, Melief CJM. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480–483. - PubMed
- Bennett SRM, et al. Help for cytotoxic T-cell responses is mediated by CD40 signaling. Nature. 1998;393:478–480. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- AI-42234/AI/NIAID NIH HHS/United States
- R37 AI026296/AI/NIAID NIH HHS/United States
- AI-10302-01A1/AI/NIAID NIH HHS/United States
- R01 AI026296/AI/NIAID NIH HHS/United States
- F32 AI010302/AI/NIAID NIH HHS/United States
- AI-26296/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials